Upgrade to SI Premium - Free Trial

Sleep Number Announces First Quarter 2026 Results

May 12, 2026 7:00 AM

Reports First Quarter 2026 Net Sales of $319 million

Advances Turnaround Through Product and Brand Reset to Drive Sustainable Growth

Continues Focus on Long-term Capital Structure Solutions, Including Strategic and Financing Options

MINNEAPOLIS--(BUSINESS WIRE)-- Sleep Number Corporation (Nasdaq: SNBR) today reported results for the quarter ended April 4, 2026.

Linda Findley, President and CEO, commented, “Q1 came in as expected given the soft start to the year, but year-over-year demand improved steadily throughout the quarter, ending with growth in March over last year. We are confident in the early positive metrics we are seeing from our new product launch and marketing campaigns, and the customer feedback on our new beds is fantastic. We believe this, combined with the full realization of our cost savings actions, puts us in line with the financial indications we highlighted in the previous earnings call.

“With the additional short-term liquidity provided by our existing lender group, we are fully focused on securing a long-term capital solution and are moving through the process of evaluating a range of strategic and financing options to maximize stakeholder value. I’m proud of the significant progress the team has made on the turnaround, and I believe we have positioned Sleep Number well for future growth.”

First Quarter Overview (all comparisons year-over-year unless otherwise noted)

Cash Flows, Liquidity and Balance Sheet Highlights (all comparisons year-over-year unless otherwise noted)

Additional Business Highlights

Sleep Number is executing a turnaround strategy centered on product, marketing and distribution with ongoing cost savings and operating efficiencies to reignite growth and increase financial resilience. Recent highlights include:

Financial Outlook

In connection with the company's previously announced engagement of Guggenheim Securities to evaluate strategic and financing options, the company is not providing financial guidance. The company, however, expects performance to be consistent with the financial indications it provided on the 2025 fourth quarter and full year earnings call. The company does not intend to provide forward-looking financial guidance while the strategic process is ongoing.

Conference Call Information

Management will host its regularly scheduled conference call to discuss the company’s results at 8:30 a.m. ET (7:30 a.m. CT; 5:30 a.m. PT) today. To access the webcast, please visit the investor relations area of the Sleep Number website at https://ir.sleepnumber.com. The webcast replay will remain available for approximately 60 days.

About Sleep Number Corporation

Sleep Number® is the leader in personalized sleep wellness. Its mattresses are designed to evolve with each sleeper to help them feel and perform their best. With adjustable firmness, pressure-relieving support and temperature balancing comfort built into every mattress, Sleep Number beds adapt to customers’ changing needs, night after night, year after year.

Backed by almost 40 years of innovation, 1,000+ patents and patents pending, and billions of hours of sleep data, Sleep Number has helped more than 16 million people achieve their best sleep. The fully integrated model ensures quality, durability, and care at every step—from design and craftsmanship to delivery and long-term support.

Sleep Number products are awarded the industry's top recognitions, including ranked #1 in customer satisfaction for mattresses purchased in-store and online, and #1 in comfort, by J.D. Power. In addition, the company is the Official Sleep + Wellness Partner of the NFL, marking a relationship that leverages players, team partnerships, and league-wide initiatives to amplify brand awareness and drive consumer engagement.

Sleep Number mattresses, bases, bedding, and furniture are available exclusively at its over 570 stores nationwide and online. To learn more, visit SleepNumber.com or a store near you.

Forward-looking Statements

Statements used in this news release relating to future plans, events, financial results or performance, such as the statements about the company’s ability to: advance and execute its turnaround to drive growth and increase financial resilience; achieve and fully realize cost savings and operational efficiencies; perform in line with its financial indications highlighted in the previous earnings call; successfully evaluate and execute strategic and financing options to achieve a long-term capital structure solution to maximize value; and realize the expected benefits from its new product portfolio and marketing initiatives are forward-looking statements subject to certain risks and uncertainties which could cause the company’s results to differ materially, including its ability to continue as a going concern as detailed in the company's Annual Report on Form 10-K for fiscal year 2025 and its Quarterly Report on Form 10-Q for the first quarter of fiscal 2026 and secure a long-term capital solution through an evaluation of strategic and financing options. The most important risks and uncertainties are described in the company’s filings with the Securities and Exchange Commission, including in Item 1A of the company’s Annual Report on Form 10-K and other periodic reports. Forward-looking statements speak only as of the date they are made, and the company does not undertake any obligation to update any forward-looking statement.

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Consolidated Statements of Operations

(unaudited – in thousands, except per share amounts)

Three Months Ended

April 4,
2026

% of
Net Sales

March 29,
2025

% of
Net Sales

Net sales

$

318,987

100.0

%

$

393,261

100.0

%

Cost of sales

134,372

42.1

%

152,726

38.8

%

Gross profit

184,615

57.9

%

240,535

61.2

%

Operating expenses:

Sales and marketing

160,795

50.4

%

189,103

48.1

%

General and administrative

33,592

10.5

%

38,619

9.8

%

Research and development

5,348

1.7

%

10,903

2.8

%

Restructuring costs

21,736

6.8

%

60

0.0

%

Total operating expenses

221,471

69.4

%

238,685

60.7

%

Operating (loss) income

(36,856

)

(11.6

%)

1,850

0.5

%

Interest expense, net

13,103

4.1

%

11,081

2.8

%

Loss before income taxes

(49,959

)

(15.7

%)

(9,231

)

(2.3

%)

Income tax expense (benefit)

338

0.1

%

(585

)

(0.1

%)

Net loss

$

(50,297

)

(15.8

%)

$

(8,646

)

(2.2

%)

Net loss per share – basic and diluted

$

(2.19

)

$

(0.38

)

Reconciliation of weighted-average shares outstanding:

Basic weighted-average shares outstanding

22,991

22,706

Dilutive effect of stock-based awards

Diluted weighted-average shares outstanding

22,991

22,706

For the three months ended April 4, 2026 and March 29, 2025, potentially dilutive stock-based awards have been excluded from the calculation of diluted weighted-average shares outstanding, as their inclusion would have had an anti-dilutive effect on our net loss per diluted share.

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Consolidated Balance Sheets

(unaudited – in thousands, except per share amounts)

subject to reclassification

April 4,
2026

January 3,
2026

Assets

Current assets:

Cash and cash equivalents

$

1,484

$

1,693

Accounts receivable, net of allowances of $656 and $694, respectively

13,354

15,502

Inventories

78,216

82,233

Prepaid expenses

19,727

13,656

Other current assets

30,694

36,873

Total current assets

143,475

149,957

Non-current assets:

Property and equipment, net

73,755

86,528

Operating lease right-of-use assets

295,315

311,723

Goodwill and intangible assets, net

66,131

66,186

Deferred income taxes

399

399

Other non-current assets

61,933

65,267

Total assets

$

641,008

$

680,060

Liabilities and Shareholders’ Deficit

Current liabilities:

Borrowings under credit facility

$

605,600

$

588,200

Accounts payable

116,395

117,977

Customer prepayments

43,338

39,527

Accrued sales returns

12,266

12,817

Compensation and benefits

19,415

14,975

Taxes and withholding

10,908

11,429

Operating lease liabilities

79,340

81,191

Other current liabilities

44,447

46,430

Total current liabilities

931,709

912,546

Non-current liabilities:

Operating lease liabilities

268,697

273,111

Other non-current liabilities

66,921

72,878

Total liabilities

1,267,327

1,258,535

Shareholders’ deficit:

Undesignated preferred stock; 5,000 shares authorized, no shares issued and outstanding

Common stock, $0.01 par value; 142,500 shares authorized, 23,049 and 22,860 shares issued and outstanding, respectively

230

229

Additional paid-in capital

34,906

32,454

Accumulated deficit

(661,455

)

(611,158

)

Total shareholders’ deficit

(626,319

)

(578,475

)

Total liabilities and shareholders’ deficit

$

641,008

$

680,060

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(unaudited – in thousands)

subject to reclassification

Three Months Ended

April 4,
2026

March 29,
2025

Cash flows from operating activities:

Net loss

$

(50,297

)

$

(8,646

)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

12,371

14,836

Stock-based compensation

2,826

3,951

Inventory obsolescence write off

2,099

Loss on disposal and impairment of leased assets

17,539

17

Deferred income taxes

(1,321

)

Changes in operating assets and liabilities:

Accounts receivable

2,148

3,291

Inventories

1,918

(724

)

Income taxes

482

736

Prepaid expenses and other assets

(4,266

)

781

Accounts payable

3,818

8,784

Customer prepayments

3,811

(6,576

)

Accrued compensation and benefits

4,354

(9,686

)

Other taxes and withholding

(1,003

)

(1,925

)

Other accruals and liabilities

(3,551

)

(6,144

)

Net cash used in operating activities

(7,751

)

(2,626

)

Cash flows from investing activities:

Purchases of property and equipment

(5,441

)

(4,599

)

Net cash used in investing activities

(5,441

)

(4,599

)

Cash flows from financing activities:

Net increase in short-term borrowings

13,805

9,087

Repurchases of common stock

(373

)

(563

)

Debt issuance costs

(449

)

(1,558

)

Net cash provided by financing activities

12,983

6,966

Net decrease in cash and cash equivalents

(209

)

(259

)

Cash and cash equivalents, at beginning of period

1,693

1,950

Cash and cash equivalents, at end of period

$

1,484

$

1,691

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Supplemental Financial Information

(unaudited)

Three Months Ended

April 4,
2026

March 29,
2025

Percent of sales:

Retail stores

87.0

%

87.6

%

Online, phone, chat and other

13.0

%

12.4

%

Total Company

100.0

%

100.0

%

Sales change rates:

Retail comparable-store sales

(17

%)

(15

%)

Online, phone and chat

(15

%)

(12

%)

Total Retail comparable sales change

(16

%)

(15

%)

Net opened/closed stores and other

(3

%)

(1

%)

Total Company

(19

%)

(16

%)

Stores open:

Beginning of period

600

640

Opened

2

Closed

(23

)

(5

)

End of period

577

637

Other metrics:

Average sales per store ($ in 000's)1

$

2,170

$

2,495

Average sales per square foot1

$

700

$

807

Stores > $2 million net sales2

31

%

51

%

Stores > $3 million net sales2

6

%

15

%

Average revenue per mattress unit3

$

6,021

$

5,992

1

Trailing twelve months Total Retail comparable sales per store open at least one year.

2

Trailing twelve months for stores open at least one year (excludes online, phone and chat sales).

3

Represents Total Retail net sales divided by Total Retail mattress units.

SLEEP NUMBER CORPORATION AND SUBSIDIARIES

Earnings before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)

(in thousands)

We define earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) as net loss plus: income tax expense (benefit), interest expense, depreciation and amortization, stock-based compensation, restructuring costs, other non-recurring items, and asset impairments. Management believes Adjusted EBITDA is a useful indicator of our financial performance and our ability to generate cash from operating activities. Our definition of Adjusted EBITDA may not be comparable to similarly titled definitions used by other companies. The table below reconciles Adjusted EBITDA, which is a non-GAAP financial measure, to the comparable GAAP financial measure:

Three Months Ended

Trailing Twelve Months Ended

April 4,
2026

March 29,
2025

April 4,
2026

March 29,
2025

Net loss

$

(50,297

)

$

(8,646

)

$

(173,609

)

$

(21,498

)

Income tax expense (benefit)

338

(585

)

36,907

(6,472

)

Interest expense

13,103

11,081

51,404

47,150

Depreciation and amortization

11,126

14,406

49,889

62,240

Stock-based compensation

2,827

3,951

5,158

11,278

Restructuring costs1

21,736

60

72,373

7,526

Other non-recurring items2

6,917

1,774

19,841

2,772

Asset impairments

1,220

Adjusted EBITDA

$

5,750

$

22,041

$

61,963

$

104,216

1

Represents costs related to business restructuring actions.

2

Non‑recurring costs represent discrete, non‑operational items, including obsolete inventory associated with the Company’s product transition, strategic alternative legal and advisory fees, executive transition and search fees, proxy contest costs, public debt issuance cost write-off, tax matters and other non‑routine professional and bank fees. These amounts are treated as permitted add-backs in the calculation of Adjusted EBITDA in accordance with the Company’s Credit Agreement.

Free Cash Flow

(in thousands)

Three Months Ended

Trailing Twelve Months Ended

April 4,
2026

March 29,
2025

April 4,
2026

March 29,
2025

Net cash used in operating activities

$

(7,751

)

$

(2,626

)

$

(8,408

)

$

(9,228

)

Subtract: Purchases of property and equipment

5,441

4,599

15,249

18,796

Free cash flow

$

(13,192

)

$

(7,225

)

$

(23,657

)

$

(28,024

)

Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands)

Three Months Ended

April 4,
2026

March 29,
2025

Operating expenses

$

221,471

$

238,685

Subtract: Restructuring costs

21,736

60

Subtract: Other non-recurring items1

4,818

1,774

Non-GAAP operating expenses

$

194,917

$

236,851

Adjusted operating expense reduction versus prior period, excluding restructuring costs and non-recurring items

$

41,934

1 Excludes inventory obsolescence write off of $2.1 million recorded in the three months ended April 4, 2026, which is included in the cost of sales line on the consolidated statement of operations.

Note - Our Adjusted EBITDA, Free Cash Flow and Adjusted Operating Expenses are considered non-GAAP financial measures and are not in accordance with, or preferable to, "as reported," or GAAP financial data. However, we are providing this information as we believe it facilitates analysis of the Company's financial performance by investors and financial analysts.

GAAP - generally accepted accounting principles in the U.S.

SLEEP NUMBER CORPORATION AND SUBSIDIARIES

Calculation of Return on Invested Capital (Adjusted ROIC)

(in thousands)

Adjusted ROIC is a financial measure we use to determine how efficiently we deploy our capital. It quantifies the return we earn on our adjusted invested capital. Management believes Adjusted ROIC is also a useful metric for investors and financial analysts. We compute Adjusted ROIC as outlined below. Our definition and calculation of Adjusted ROIC may not be comparable to similarly titled definitions and calculations used by other companies. The tables below reconcile adjusted net operating profit after taxes (Adjusted NOPAT) and total adjusted invested capital, which are non-GAAP financial measures, to the comparable GAAP financial measures:

Trailing Twelve Months Ended

April 4,
2026

March 29,
2025

Adjusted net operating profit after taxes (Adjusted NOPAT)

Operating (loss) income

$

(85,299

)

$

19,180

Add: Operating lease interest1

23,832

26,098

Less: Income taxes2

7,902

(10,022

)

Adjusted NOPAT

$

(53,565

)

$

35,256

Average adjusted invested capital

Total deficit

$

(626,317

)

$

(456,844

)

Add: Long-term debt3

605,720

557,921

Add: Operating lease liabilities4

348,037

376,909

Total adjusted invested capital at end of period

$

327,440

$

477,986

Average adjusted invested capital5

$

408,437

$

487,361

Adjusted ROIC6

(13.1

%)

7.2

%

1

Represents the interest expense component of lease expense included in our financial statements under ASC 842, Leases.

2

Reflects annual effective income tax rates, before discrete adjustments, of 12.9% and 22.1% for April 4, 2026 and March 29, 2025, respectively.

3

Long-term debt includes existing finance lease liabilities.

4

Reflects operating lease liabilities included in our financial statements under ASC 842.

5

Average adjusted invested capital represents the average of the last five fiscal quarters' ending adjusted invested capital balances.

6

Adjusted ROIC equals Adjusted NOPAT divided by average adjusted invested capital.

Note - The Company's Adjusted ROIC calculation and data are considered non-GAAP financial measures and are not in accordance with, or preferable to, "as reported," or GAAP financial data. However, we are providing this information as we believe it facilitates analysis of the Company's financial performance by investors and financial analysts.

GAAP - generally accepted accounting principles in the U.S.

Investor Contact: [email protected]

Media Contact: Muriel Lussier, [email protected]

Source: Sleep Number Corporation

Categories

Business Wire Press Releases